By Catherine Eckford2024-05-21T16:35:24
The EGFR immune engager in combination with pembrolizumab is expected to be administered to the first patients in late 2024.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-03T12:02:00Z
2026-05-29T10:14:00Z
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2025-10-22T14:00:00
Sponsored by Bruker
Site powered by Webvision Cloud